ESPR Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own ESPR shares is 225, representing 66.11% of the company's common stock.

PRUDENTIAL FINANCIAL INC, in the last quarter, reduced its stake in ESPR by -3.61% restricting it's holding to 32.06 thousand shares of worth nearly $85.92K. PRINCIPAL FINANCIAL GROUP INC also lessened -13.33% of the ESPR shares from its portfolio, reducing its holding to 29.15 thousand shares of worth $78.13K. PLATINUM INVESTMENT MANAGEMENT LTD also shunned ESPR shares holding by -43.16% last quarter which brought its holding to 1.6 million shares worth $4.28M.

As per its latest 13F filing, ORBIMED ADVISORS LLC increased its stake in ESPR by 100% in the last quarter. The institutional holder raised its holding to 13.71 million shares having worth more than $36.74M. CTC ALTERNATIVE STRATEGIES, LTD. also added 100% more shares of ESPR to its portfolio, raising its holding to 37.1 thousand shares of worth $99.43K. OMERS ADMINISTRATION CORP also increased its ESPR shares holding by 100% which brought its holding to 32.2 thousand shares worth $86.30K.

The insider with the most stakes in ESPR is BIOTECH TARGET N V , 10 percent owner at the company. Additionally, ESPR stock is highly held by director JANNEY DANIEL and 10 percent owner Boxer Capital, LLC among others.

Company executives, directors, and other insiders own 0.36% percent of Esperion Therapeutics, Inc.'s stock. Within the last six months, there have been 10 transaction(s) in which ESPR insiders have sold stock, totaling 35.73K shares. Insiders that have sold shares include WARREN ERIC, HALLADAY BENJAMIN, and KOENIG SHELDON L..

There have been 0 transaction(s) during the past 6-months in which Esperion Therapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 2.95M Esperion Therapeutics, Inc. shares are held by insiders, which represents about 0.36% of ESPR stock.

ESPR 10 percent owner, BIOTECH TARGET N V holds the largest portfolio of the company's shares. ESPR shares owned by BIOTECH total nearly 4.48 million.

ORBIMED ADVISORS LLC is the largest institutional owner in ESPR which holds 13.71 million shares worth $36.74M or 12.2% of the total ESPR shares outstanding followed by CTC ALTERNATIVE STRATEGIES, LTD. with ownership of 37.1 thousand shares representing 0.03% of the ESPR ownership. EATON FINANCIAL HOLDINGS COMPANY, LLC is the third largest stakeholder with 34.03 thousand shares or 0.03% of the ownership worth more than $91.20K.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the ESPR is concerned, it is a stock which is optionable.

Number of ESPR shares short is 32.35M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 197.04M shares of ESPR are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, ESPR has 195.63M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for ESPR is 3.9.